



WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.

Our Vision

“Every drug can be made and every disease can be treated”



Global Platform. One Vision.

Contact us


☎ 400-820-0985 (China)
857-413-2800 (U.S.)
+86 (21) 2066-3734 (Global)

✉ wuxiconcierge@wuxiapptec.com

🌐 www.wuxiapptec.com


WuXi AppTec
603259.SH/2359.HK

Integrated End-to-End CRDMO Enabling Platform



WuXi Chemistry

Integrated, end-to-end chemistry research, development, and commercial manufacturing services.




WuXi Biology

A full spectrum of biology services and solutions supporting stand-alone and integrated projects.



WuXi Testing

Seamless drug testing services from preclinical testing to clinical trials.



WuXi Chemistry

A comprehensive CRDMO platform that moves molecules from discovery to market. Capacity and capabilities to support all phases of drug development at any scale for all synthetic molecular modalities.



- **440,000+** compounds (in the past 12 months); **3,409** preclinical, clinical and commercial drugs, including **84** Phase III clinical candidates and **76** commercial drugs (as of Q4 2024)
- Successful inspections by U.S. FDA, EU EMA, China NMPA, Japan PMDA, South Korea MFDS, and SwissMedic, and over **100** country approvals for branded drugs
- **700+** CMC submission packages written to support global IND and NDA filings from 2019 to 2024

WuXi Research Chemistry Services

Small Molecule Discovery

Medicinal Chemistry | Custom Synthesis | Library | Discovery Process Chemistry

- Delivered 440,000+ compounds (in the past 12 months)
- **Technology Platform:** Reaction Conditions Screening, Photoredox Chemistry, Flow Chemistry, Biocatalysis, Electrochemistry, Computer-Aided Drug Design
- **Specialty Chemistry:** Targeted Covalent Inhibitor, Targeted Protein Degradator, Fluorine Chemistry, Carbohydrate, Macrocyclic, Organoboron, Stable Isotope Labeling

WuXi TIDES

Peptide and Oligonucleotide Discovery, Development, Manufacturing

Oligonucleotides | Peptides | Conjugates | Amidites | Unnatural Amino Acids | Linkers | Ligands

- Simplifying TIDES drug development by providing discovery, CMC development and the entire manufacturing supply chain under one roof
- Over 20 oligonucleotide production lines at all scales
- 41,000 L peptide solid phase total reactor volume
- **Novel technology platforms:** Biocatalysis, Thin Film Evaporation, TFF/precipitation, Continuous Purification

WuXi STA

Small Molecule Development and Manufacturing


Drug Substance | Drug Product | Analytical | Regulatory Dossier Preparation

- Approximately 4,000 m³ total reactor volume for small molecule API and intermediate manufacturing
- **Drug Substance Enabling Technology Portfolio:** Crystallization & Particle Engineering, Biocatalysis, Chemo Catalysis, Flow Chemistry, Preparative HPLC & SFC & SMB, High Potency API
- **Drug Product Enabling Technology Portfolio:** Spray Dried Dispersion, Nano Suspension, Hot Melt Extrusion, Lipid Nanoparticle, High Potency Drug Product
- 5 drug product sites in North America, Europe, and Asia, supporting both oral solid and parenteral dosage forms



WuXi Biology

A comprehensive spectrum of biology services and solutions, supporting stand-alone and integrated projects, from target discovery to hit finding, lead optimization, candidate selection, and beyond.




- **Comprehensive** discovery and translational biology centers, with ~3,000 experienced scientists and global footprints in 9 sites
- Early discovery screening platform, providing diverse hit finding solutions such as DEL/HTS/ASMS/FBDD* and virtual screening, supported by informatics and data sciences
- **Thousands** of validated, 'ready to go', *in vitro* assays and *in vivo* models enabling discovery biology for comprehensive target classes, therapeutic areas and modalities
- Extensive **Oncology, Immunology, Infectious Disease, Inflammation, Neuroscience, Rare disease and Metabolic Disease Indication**, offering an end-to-end service from discovery, through optimization and into clinical development
- **AAALAC** accredited and **BSL-2** certified on multiple sites
- Pathology and **CAP-certified** FACS capabilities supporting clinical biomarker services

Modalities

- Small molecules and peptides
- Oligonucleotides
- Bi-functional molecules, e.g. ADC/PDC/POC/TPD*
- Vaccines

Early Discovery

- New target discovery and mechanistic study
- Protein production & structural biology
- Screening & hit identification: DEL/HTS/HTC/ASMS/FBDD/Display/VS and libraries for small molecules, covalent, peptides, TPD* & macrocycles



Lead Optimization

- *In vitro* biochemistry and cell biology
- Cell panel screening
- MOA studies
- Radiometric assays
- Clinical biomarker development and validation


In Vivo pharmacology

- Comprehensive *In vivo* disease model collection
- Targeted oncology and immuno-oncology
- Drug resistance and other novel models of higher translational value
- Tumor model database

*HTS: High Throughput Screening; DEL: DNA Encoded Library; ASMS: Affinity Selection Mass Spectrometry Screening; FBDD: Fragment-based Drug Discovery; TPD: Targeted protein degradation

WuXi Testing - Drug R&D Testing

An integrated testing platform across the full life cycle of discovery and development to deliver innovative medicines to patients.



- Comprehensive *in vitro* and *in vivo* global DMPK services
- Preclinical services including GLP toxicology and safety pharmacology for successful Investigational New Drug (IND) / New Drug Application (NDA) filings
- GLP global bioanalytical services based on both LC-MS/MS and immunochemistry platforms



WuXi IND (WIND): A full IND one-package submission that includes WuXi CMC, preclinical (disease specific pharmacology, DMPK, toxicology, and bioanalysis), clinical and regulatory affairs services.



Long term toxicology, developmental DMPK and clinical bioanalysis in conjunction with clinical & CMC services that enable customers to move the molecules from IND to NDA.

WuXi Testing - Clinical Research

Comprehensive solutions for pharmaceuticals, covering bioequivalence, Phase I to Phase IV clinical development services, and Real World Study.



- Enable global clinical development through operation in China, the U.S, and Australia; **12** offices and **550+** employees worldwide, **2,800+** clinical trial sites globally including **1700+** sites in China
- Average **10**-year industry experience for Project Management (PM) / Clinical Operations (CO) / Biostatistics and Regulatory Affairs teams
- Successfully conducted **1,100+** clinical trial studies
- **5,000+** experienced CRCs in around **150** cities across China
- Site management services for **4,000+** Phase I-IV clinical trial projects, in which **300+** new drugs passed China NMPA, EMA and U.S. FDA inspection supporting their final approval by regulators

Clinical Development Services


- PM/Clinical Operation
- Regulatory Affairs
- Medical Affairs
- Pharmacovigilance
- Quality Systems Management & Consulting
- Medidata Rave EDC
- Early Clinical Development
- eCTD, PV System

- SMO Services (Site Operation)
- Patient Recruitment & Management
- Site Network Covering 1,000+ Sites
- Feasibility & Site Selection
- Fast Site Start-up
- PMS & Academic Research Organization RWS

Site Management Organization

Our Continued Commitment to Sustainability

As a responsible corporate citizen, WuXi AppTec remains steadfast in its commitment to patients, customers, investors, employees, and communities to operate in a sustainable way both today and in the future.



Improved governance structure

- The Board of Directors empowered the ESG Committee to oversee and manage our ESG strategies, policies, and performance. The ESG Office and Working Group are responsible for executing the action plans.

Upholding Business Ethics Standards

- Compliance with All Applicable Laws in Operating Jurisdictions and Highest Business Ethics Standards. In 2024, Company's **24** sites achieved ISO 27001 certifications.

Reduce environmental impact

- WuXi AppTec commits to reducing absolute Scope 1 and Scope 2 GHG emissions by **42%** , and absolute Scope 3 GHG emissions by **25%** by 2030, based on 2024 levels.

Give back to local communities

- By following the Company's Philanthropy and Sponsorship Policy and Principles, we continuously manage our philanthropic actions strategically to actively serve the community.

As a member of the United Nations Global Compact (UNGC), we committed to supporting its ten sustainability principles.

As a Supplier Partner of the Pharmaceutical Supply Chain Initiative (PSCI), we committed to adhering to PSCI Principles.

WuXi AppTec earns the Science Based Targets initiative (SBTi) validation for near-term emissions reduction targets.

Unwavering Commitment to Guarding Customers' IP and Adhering the Highest Standards of Quality & Compliance

802¹
Quality Audits & Inspections by Global Customers, Regulatory Authorities and Independent Third Parties in 2024

100%
Pass Rate with 0 Critical Findings



58
Information Security Audits by Global Customers in 2024, with 0 Critical Findings

24²
Main Operating Sites are ISO/IEC 27001 Certified

Robust Data Privacy and Security System



Data security and privacy protection are among our highest priorities. Since our founding, WuXi AppTec has maintained a strong track record of data privacy based on rigorous security processes. Everything we discover, develop and deliver to our customers is secure, separated and protected.

Adhering to Global Regulatory Standards

- CMC platform (drug substance, drug product, analytical and regulatory CMC support) received FDA approval for New Chemical Entities
- CDMO approved by regulatory agencies in U.S., Canada, EU, Switzerland, China, Australia and New Zealand to supply APIs, GMP intermediates for branded commercial drugs
- First CDMO to support the approval of an innovative drug in China through the Marketing Authorization Holder ("MAH") pilot program
- GLP toxicology laboratory certified by both OECD and NMPA, and passed FDA and NMPA inspections
- GLP/GCP bioanalytical laboratory passed FDA, OECD, NMPA and PMDA inspections



Fighting Diseases by Enabling High-Quality Medicines Faster

Advanced development of therapy approved by FDA and NMPA for the treatment of adult patients with **chronic hepatitis C virus genotypes 1 and 4 infections**

Supported the development of the first oral therapy approved by FDA and NMPA for the treatment of patients with chronic lymphocytic leukemia, **mantle cell lymphoma** and **Waldenström's macroglobulinemia**

Provided all-round support for a BTK inhibitor to receive accelerated NDA approval for treatment of **mantle cell lymphoma** from FDA

Advanced development of first oral-targeted therapy approved by FDA for the treatment of adult patients with **relapsed or refractory acute myeloid leukemia** with an isocitrate dehydrogenase-2 mutation

Supported the acquisition of implied license of clinical trial from FDA for a small molecule drug for the treatment of **Alzheimer's Disease**

Expedited an NDA submission to receive FDA approval for a breakthrough treatment of **ovarian cancer**

Awards and Industry Recognition Partially Listed

Industry Leadership

FROST & SULLIVAN

Global Contract Research Development and Manufacturing Organization Company of the Year (2022-2024)



TIME magazine's "World's Best Companies" in Sustainable Growth 2025

FORTUNE

Ranked among "The Future 50" (2020-2021)



50 Smartest Companies (2019)



Company of the Year (2018)



Heroes of Chemistry Award (2017)



Best Company in an Emerging Market (2014)

ESG Ratings



Received MSCI ESG "AAA" Leader Rating in 2025



First achieved a leadership level of "A" in 2024 CDP Water Security rating



First Gold Medal awarded in 2024 EcoVadis sustainability rating



Enabler of Innovation




Trusted Partner



Global Contributor

A Global Footprint



China

Shanghai	R&D Headquarters / Drug Discovery and Preclinical/Clinical / Regulatory
Jinshan (Shanghai)	Small Molecule R&D and Manufacturing
Changzhou	Small Molecule R&D and Manufacturing
Suzhou	Drug Safety Evaluation
Nanjing	DMPK and Bioanalytical
Nantong	Small Molecule R&D
Taixing	Small Molecule R&D and Manufacturing
Changshu	Small Molecule R&D and Manufacturing
Wuxi	Small Molecule Manufacturing
Tianjin	Chemistry and Drug Discovery
Chengdu	Drug Discovery and Preclinical / Clinical
Wuhan	Chemistry and Drug Discovery / Clinical
Beijing	Clinical / Regulatory
Guangzhou	Program Management / Clinical

South Korea

Pan-Gyo	Program Management
---------	--------------------

U.S.

Boston / Natick	MA	Compound Management / Logistics Center / Program Management
Cranbury	NJ	DMPK and Biology
Plainsboro	NJ	Bioanalytical Testing
Austin	TX	Clinical Development Service
San Diego	CA	Biology / Small Molecule Process Development and Manufacturing
Middletown	DE	Small Molecule Manufacturing

Germany

Munich	Drug Discovery /Biology
--------	-------------------------

Switzerland

Couvet	Small Molecule Manufacturing
--------	------------------------------

Israel

Tel Aviv	Program Management
----------	--------------------

Singapore

Singapore	Small Molecule R&D and Manufacturing
-----------	--------------------------------------

Japan

Kyoto	BD / Program Management
-------	-------------------------

**Key global sites listed